Physicians' Academy for Cardiovascular Education

Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial

3' education - June 1, 2023 - Ahmad Masri, MD

SGLT2i in the spectrum of CKD: A call for action

10' education - June 1, 2023 - Meg Jardine, MD, PhD

Benefits of rapid uptitration of HF medications independent of baseline renal function

3' education - May 30, 2023 - Jozine ter Maaten, MD, PhD

Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF

3' education - May 30, 2023 - Jasper Brugts, MD, PhD

The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

10' education - May 26, 2023 - Lale Tokgözoğlu, MD

The right therapy for the right patient

3' education - May 25, 2023 - Stephen Nicholls, MD

ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

3' education - May 25, 2023 - Robert Mentz, MD

Causes of coronary thrombosis

3' education - May 25, 2023 - Renu Virmani, MD

Relevance of adipose tissue in cardio-metabolic complications

3' education - May 25, 2023 - Antonio Vidal-Puig, MD

Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis

3' education - May 25, 2023 - Marianna Fontana, MD, PhD

A publication on CV risk in autoimmune diseases

3' education - May 24, 2023 - Jeanine Roeters van Lennep, MD, PhD and Pierre Sabouret, MD, PhD

Interorgan communication in the development of atherosclerosis

3' education - May 23, 2023 - Filip Swirski, PhD

How to manage patients with elevated Lp(a)

3' education - May 23, 2023 - Florian Kronenberg, MD, PhD

Elevated inflammation markers in diabetes: a cause or a consequence?

3' education - May 23, 2023 - Peter Libby, MD

Innovations in lipid therapy

3' education - May 22, 2023 - Peter Libby, MD

Single P2Y₁₂ inhibitor therapy directly after PCI in NSTEMI - a pilot study

5' education - May 16, 2023 - Niels van der Sangen, MD

Reassessing the role of triglycerides in residual cardiovascular risk

10' education - May 16, 2023 - Richard Hobbs, MD

The latest evidence of SGLT2i in CKD

10' education - May 16, 2023 - Will Herrington, MD

New opportunities to tackle the global burden of CKD – the role of SGLT2i

10' education - May 9, 2023 - Adeera Levin, MD

4-year follow-up data on efficacy and safety of PCSK9 siRNA

5' education - May 8, 2023 - Kausik Ray, MD

Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial

3' education - June 1, 2023 - Ahmad Masri, MD
**ESC Heart Failure 2023** Ahmad Masri shares the results of the REDWOOD-HCM Cohort 4 trial, a phase 2 study with aficamten in non-obstructive HCM.

ESC Heart Failure 2023 Ahmad Masri shares the results of the REDWOOD-HCM Cohort 4 trial, a phase 2 study with aficamten in non-obstructive HCM.

SGLT2i in the spectrum of CKD: A call for action

10' education - June 1, 2023 - Meg Jardine, MD, PhD
Treatment with SGLT2i lead to profound risk reductions in CKD. Meg Jardine discusses how we can improve implementation of SGLT2i for CKD in clinical practice.

Treatment with SGLT2i lead to profound risk reductions in CKD. Meg Jardine discusses how we can improve implementation of SGLT2i for CKD in clinical practice.

Effects of SGLT2i are not modified by gout history in patients with HF

Literature - May 31, 2023 - Butt JH, et al. - JAMA Cardiol. 2023

In a pooled post hoc analysis of DAPA-HF and DELIVER the benefits of dapagliflozin were independent of gout status in patients with HF across the spectrum of LVEF.

Intermittent fasting plus early time-restricted eating in adults at risk of T2DM

Literature - May 31, 2023 - Tong Teong X, et al. - Nat Med. 2023

Does intermittent fasting plus early time-restricted eating provide greater improvements in glycemic control, weight management or CV markers compared to calorie restriction or standard care in adults at risk of T2DM? The authors investigated this in a three-arm parallel group sequential RCT.

Icosapent ethyl improves coronary hemodynamics

Literature - May 31, 2023 - Rabbat MG, et al. - Eur Heart J Cardiovasc Imaging. 2023

In an analysis of the EVAPORATE trial with prespecified endpoints, icosapent ethyl improved CT angiography–derived fractional flow reserve of coronary lesions after 9 and 18 months compared with placebo.

Benefits of rapid uptitration of HF medications independent of baseline renal function

3' education - May 30, 2023 - Jozine ter Maaten, MD, PhD
**ESC Heart Failure 2023** Jozine ter Maaten shares the results of a subanalysis of STRONG-HF, which investigated the effects of high intensity HF care on renal function.

ESC Heart Failure 2023 Jozine ter Maaten shares the results of a subanalysis of STRONG-HF, which investigated the effects of high intensity HF care on renal function.

Non-coding variant in LPA gene associated with unexplained FH

News - May 30, 2023

EAS Congress 2023 A Genome Wide Association Study in the 100,000 Genomes Project showed that a rare non-coding variant in the LPA gene is associated with mutation negative FH.

TSAT as marker for iron deficiency best predicts response to intravenous iron in patients with HFrEF

News - May 30, 2023

ESC Heart Failure 2023 Using data from IRONMAN, it was examined which marker of iron deficiency (TSAT, serum ferritin or anemia) best predicts response to intravenous iron in patients with HFrEF.

Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF

3' education - May 30, 2023 - Jasper Brugts, MD, PhD
**ESC Heart Failure 2023** Jasper Brugts summarizes the results of the MONITOR-HF trial, which investigated the efficacy of remote hemodynamic monitoring vs. standard care in patients with chronic HF.

ESC Heart Failure 2023 Jasper Brugts summarizes the results of the MONITOR-HF trial, which investigated the efficacy of remote hemodynamic monitoring vs. standard care in patients with chronic HF.

The benefits of icosapent ethyl in addressing residual risk: What is the evidence?

10' education - May 26, 2023 - Lale Tokgözoğlu, MD
Lale Tokgözoğlu provides an overview of studies that investigated the effects of omega-3 fatty acids with a focus on icosapent ethyl.

Lale Tokgözoğlu provides an overview of studies that investigated the effects of omega-3 fatty acids with a focus on icosapent ethyl.

The right therapy for the right patient

3' education - May 25, 2023 - Stephen Nicholls, MD
**EAS Congress 2023** Stephen Nicholls is the recipient of the 2023 Anischkow Award. He summarizes the key messages of his lecture “Personalized Prevention of Atherosclerotic Cardiovascular Disease”.

EAS Congress 2023 Stephen Nicholls is the recipient of the 2023 Anischkow Award. He summarizes the key messages of his lecture “Personalized Prevention of Atherosclerotic Cardiovascular Disease”.

ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

3' education - May 25, 2023 - Robert Mentz, MD
**ESC Heart Failure 2023** Robert Mentz presents the results of PARAGLIDE-HF, which reported greater reduction in NT-proBNP in the sacubitril/valsartan group vs. the valsartan group in HFmrEF/HFpEF after a worsening HF event.

ESC Heart Failure 2023 Robert Mentz presents the results of PARAGLIDE-HF, which reported greater reduction in NT-proBNP in the sacubitril/valsartan group vs. the valsartan group in HFmrEF/HFpEF after a worsening HF event.